目的 观察柴胡疏肝丸联合莫沙比利片治疗肝胃不和型功能性消化不良(FD)的疗效.方法 将58例确诊为肝胃不和型FD患者按就诊顺序分为2组:治疗组用柴胡疏肝丸(6 g·次-1,3次·d-1 )联合莫沙比利片(5 mg·次-1,3次·d-1)口服;对照组仅口服莫沙比利片5 mg·次-1,3次·d-1,疗程均为28 d.患者服药前和治疗后第56天随访时填写SF-36生活质量量表;评定治疗后第7、14、28、56天的疗效,并记录不良反应.结果 2组治疗后第7、14天疗效比较差异无统计学意义(P＞0.05).治疗第28、58天治疗组症状改善显效率均高于对照组(62.1% vs 34.5%,62.1% vs 31.0%,均P<0.05).2组SF-36生活质量量表的8个维度积分除生理功能外,余项较治疗前均得到了显著改善(P<0.05或P<0.01);治疗后治疗组较对照组的总体健康、活力、情感职能、精神健康4个维度项均有显著提高(P<0.05或P<0.01).结论 柴胡疏肝丸联合莫沙比利片治疗肝胃不和型FD的后期及远期疗效要优于单纯应用莫沙比利片治疗,而且能更好地提高患者的生活质量.%Objective To explore the clinical effect of Chaihu Shugan pills (CSPs) combined with mosapride citrate tablets (MCTs) on functional dyspepsia (FD) due to liver-stomach disharmony. Methods Fifty-eight patients with FD due to liver-stomach disharmony were treated with 5 mg MCTs (control group) or in combination with 6 g CSPs (treatment group) 3 times per day. The course of treatment was 28 days. The 36-item Short-Form health survey (SF-36) was performed before and 56 days after treatment. The clinical effects were assessed at 7,14,28 and 56 days after treatment. Results There was no significant difference between treatment group and control group in the effective rate at 7 and 14 days after treatment (P>0. 05). However,symptom improvement rate in treatment group was obviously higher than that in control group at 28 and 56 days after treatment (62. 1% and 62. 1% vs 34. 5% and 31. 0% , respectively; P< 0. 05). The scores for the 7 of 8 SF-36 domains (except physical function) were significantly improved after treatment (P展开▼
